U.S. Department
of Justice
Photo Gallery
DOJ/FTC Host Listening Session on Lowering Americans’ Drug Prices Through Competition
“We are here today because President Trump has given us a mandate under several executive orders to investigate anti-competitive practices in the pharmaceutical industry and to take decisive action to combat those practices.”
-Assistant Attorney General for Antitrust Abigail Slater
“We do not condone rent seeking that blocks or raises the price of generic or bio-similar treatments and we must be vigilant that regulatory barriers do not unnecessarily favor incumbents or make markets susceptible to this rent seeking.”
-Assistant Attorney General for Antitrust Abigail Slater
“...I know that these topics touch many other people and businesses in America, and we want to hear from you because we work for you at the end of the day. If you have concerns about specific anti-competitive practices, please reach out to the DOJ and FTC directly or through the healthy competition complaint center: HealthyCompetition.gov”
-Assistant Attorney General for Antitrust Abigail Slater
On June 30, 2025, the Department of Justice’s Antitrust Division and the Federal Trade Commission jointly hosted the first of three listening sessions to discuss drug pricing.
Updated July 3, 2025
Related Content:
Topic
Antitrust
Component or Office